• Distinguished Professor, Zhengzhou University, Zhengzhou, China

Foreign Academician, Russian Academy of Natural Sciences;

Chair, Committee of Hypoxia Cancer Biology, Chinese Anti-Cancer Association.

Henan Provincial High-Level Talent

Former Professor and Vice Chair, Department of Pathology; and Director, Center of Environmental Exposure, Thomas Jefferson University, Philadelphia, USA

Former Endowed Chair Professor of Cancer Research, Professor of University of Iowa, Iowa City, USA

• Associate Editor, Genes & Diseases; editorial boards of The FEBS Journal, Plos One and Frontiers in Bioscience.
• Bing-Hua Jiang initially identified and cloned hypoxia-inducible factor-1 (HIF-1), characterized HIF-1 functional domains and oxygen-sensing regulation as well as its role in cancer and ischemic disease, a discovery that laid the foundation for the 2019 Nobel Prize in Physiology or Medicine. He also pioneered the identification of the PI3K/AKT pathway’s role in tumor angiogenesis and cancer progression, establishing a molecular framework now widely adopted in cancer biology and therapy research. He obtained many NIH R01 grants and published more than 230 articles with more than 45,000 citations (H-index 91). He has had a transformative impact on hypoxia, cell signaling, angiogenesis, and cancer therapeutic resistance, and obtained several prestigious Awards including The First Prize of the National Science and Technology Progress Award and American Cancer Society Research Scholar Award.

• Tenured Professor, St. John’s University, USA

Director, Laboratory of Cancer Pharmacology, College of Pharmacy

Former Director, Institute of Biotechnology (2016–2024)

Distinguished/Visiting Professor at Sun Yat-sen University, Sichuan University, Beijing University of Chinese Medicine, and others

• Editor-in-Chief of Drug Resistance Updates and Recent Patents on Anticancer Drug Discovery; Specialty Chief Editor of the Cancer Cell Signaling section and Frontiers in Oncology; Senior Editor of Biomolecules and Biomedicine.
• Professor Zhe-Sheng Chen is a world-renowned expert in cancer multidrug resistance (MDR) and its reversal. He is also on the editorial board of over 30 journals, including Cancer Letters, MedComm, and Chinese Medicine, and acts as a reviewer for more than 200 international journals, including Science and Nature As a globally recognized grant reviewer, he has evaluated proposals for NIH (USA), NSFC (China), and funding agencies in Canada, France, the Netherlands, and other countries.His research has significantly advanced our understanding of MDR mechanisms and the development of therapeutic reversal agents. He has published over 500 SCI papers in high-impact journals such as Chemical Society Reviews, Nature Communications, Advanced Materials, and Molecular Cancer, with more than 36,000 citations and an H-index of 93. He holds 7 invention patents (from the US and China) and has authored or edited 15 English books. His accolades include the AACR Young Scientist Award, the St. John’s University Achievement Award, and 14 Outstanding Faculty Awards, as well as recognition in the “Lifetime Scientific Influence Ranking” and the “2023 Global Scientific Influence Ranking.”

• Dean, Institute of Translational Medicine, Zhejiang University

Deputy Dean, School of Medicine, Zhejiang University

Changjiang Scholar Chair Professor (Ministry of Education, China)

Chief Scientist, National Center for Fundamental Science

Chief Scientist, National Key R&D Program of China

Former Ruby E. Rutherford Distinguished Endowed Professor, MD Anderson Cancer Center

Founding Director, Cancer Metabolism Program, MD Anderson Cancer Center

Foreign Member, Academia Europaea (2021)

Chinese Medical Science and Technology Award – International Scientific and Technological Cooperation Award (2022)

• Editor-in-Chief of Visualized Cancer Medicine; Deputy Editor-in-Chief of Journal of National Cancer Center; Editorial Board Member for journals including Cell Research, The Journal of Biological Chemistry, among others.
• Zhi-min Lu published more than 150 research articles in top peer-reviewed journals, and about 70 of these papers, as a corresponding author, were published in Cell, Nature, Nature Cell Biology, Cancer Cell, Nature Cancer, Cancer Discovery, Cell Metabolism, Molecular Cell, Nature Metabolism, Nature Structural and Molecular Biology, Science Advances, Nature Reviews Molecular Cell Biology, Nature Reviews Cancer, Annual Review of Biochemistry, Trends in Cell Biology, Trends in Cancer, and Trends in Biochemical Sciences.

• Professor, Department of Biomedical Sciences, College of Biomedicine, City University of Hong Kong.

Panel member of The Biology and Medicine of RGC/NSFC (Joint Research Scheme, JRS) since 2023.

• Editorial Board Members of Signal Transduction and Target Therapy, MedComm and American Journal of Cancer Research; Guest Editor of Pathogens, Biomedicines and Pharmaceutics; Associate editor of Genes & Diseases
• Ming-Liang HE has been focusing on the molecular mechanisms of human diseases caused by virus infections (including human cancers and acute infectious diseases) and target-specific antiviral/antitumor drug development. He was among the earliest scientists studying the severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV-1) in 2003. He has published near 200 research/review articles in high profile research journals (such as Nat Chem, JAMA, STTT, PNAS, Cancer Res., Adv. Mater., Adv. Sci., Adv. Funct. Mater., Nat. Cummun., Biomaterials, J. Infect., etc) with over 11,000 citations and H-index of 63. He has granted quite a few US and Chinese patents.

• Professor, Sun Yat-sen University Cancer Center

Principal Investigator, State Key Laboratory of Oncology in South China

Director, Center for Cancer Metabolism and Intervention Research, Sun Yat-sen University Cancer Center

Director, Platform for Metabolomics Technology, Sun Yat-sen University

• Executive Editor-in-Chief, Cancer Communications; Associate Editor, Cancer & Metabolism
• Peng Huang obtained his medical degree from Sun Yat-sen University School of Medicine and his PhD Degree from the University of Texas Health Sciences Center in Houston. He was an Ashbel Smith Endowed Professor at the University of Texas MD Anderson Cancer Center before he joined Sun Yat-sen University Cancer Center. His research interests are in the areas of cancer metabolism, ROS/redox signaling, mitochondrial biology, and therapeutic strategies/drugs that target the abnormalities in cancer metabolism. His research has led to a series of publications in Nature, Cell, Nature Medicine, Cancer Cell, Nature Cell Biology, Nature Reviews Drug Discovery, and other professional journals. He has been recognized as a highly cited scholar for the past seven consecutive years.

• Chair Professor, Shanghai Jiao Tong University

Director, Institute of Cell and Gene Therapy

Former Ronald L. Whisler Endowed Chair Professor, The Ohio State University

Distinguished Expert, National High-Level Overseas Talent Program

NSFC Outstanding Young Investigator (Overseas)

President, Basic Immunology Branch, Asia-Pacific Biomedical Immunology Association

Chair, Biological Therapy Branch, Chinese Health Management Association

President, Songjiang Association for Science and Technology, Shanghai

• Honorary Editor-in-Chief of iCELL. Editor-in-Chief of Am J Clin Exp Immunol; Associate Editor of MedComm and Front Immunol; Editorial Board Member of Cytokine Growth Factor Rev, Cell Mol Immunol, Mol Ther, J Mol Cell Biology, Theranostics, and View.
• Professor Song-Guo Zheng is a pioneering founder in the discovery and nomenclature of inducible regulatory T cells (iTregs), with long-standing expertise in T cell regulation, autoimmunity, and tumor immunology. He has published over 230 SCI papers, ( 20 ≤ IF ≤ 50: 18 papers, 10 ≤ IF ≤20: 49 papers), accumulating over 20,000 citations and an H-index exceeding 80. He has led multiple NIH and national key research projects and authored four English monographs. His accolades include the NIH STAR Award, ACR Distinguished Investigator Award, Dona Immunologist Award, Freda Newton Memorial Scholar Award, and Edmund Dubois Award, among more than 20 international honors.

• Director, Professor, and Senior Investigator, Institute of Cancer Prevention and Treatment, Guangdong-Hong Kong-Macao Greater Bay Area Institute of Precision Medicine (Guangzhou)

Professor Emeritus, Duke University School of Medicine

Tenured Professor, Duke University School of Medicine

Tenured and Endowed Professor, The University of Texas MD Anderson Cancer Center

Changjiang (Yangtze River) Chair Professor, Ministry of Education of China

• Founding Editor-in-Chief of Cancer Medicine; Executive Editor of Journal of Biomedical Research
• Professor Qingyi Wei has made pioneering contributions to the fields of DNA damage repair, cell death, genomics, and the molecular epidemiology of cancer development and prognosis. He has been devoted to elucidating cancer mechanisms and advancing precision prevention strategies. He has published over 600 SCI papers, with more than 46,700 citations and an h-index of 106, demonstrating his far-reaching academic impact.

• Senior Principal Investigator, Senior Principal Scientist，Bioinformatics Institute (BII), ASTAR

Head, Intelligent Digital and Molecular Pathology (iDMP) Lab

Adjunct Assoc. Professor, Department of Pathology and Department of Biochemistry, YLL School of Medicine, National University of Singapore (NUS)

Adjunct Assoc. Professor, School of Biological Sciences, Nanyang Technological University (NTU)

Co-founder, A!maginostic Pte. Ltd.

• Weimiao YU has been contributing to the fields of computational pathology and biomedical AI, with a multidisciplinary background that began with his early research on collective cell migration and tissue morphogenesis. Building on this foundation, he has expanded his focus to the integration of artificial intelligence in digital pathology and multiplex immunofluorescence (mIF) imaging. He has been leading in the development of AI-assisted platforms such as A!Prostate, A!HistoClouds and A!Prostate etc., and currently leads the AIDP Programme—an SGD 16.4 million national initiative to build annotated pathology databases, diagnostic tools and large scale adoption of AI solutions in clinical practice. Over the 20 years, he has helped secure research funding exceeding SGD 28 million and has fostered collaborations across academic, clinical, and industry domains. Committed to bridging research and practical application, Prof. Yu’s work aims to support diagnostic innovation and translational progress in oncology.